HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by t
HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process.
HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.
Our purpose is to improve world health by empowering patients suffering from a wide spectrum of liver diseases to obtain improved knowledge of liver health, thereby enhancing clinical management, therapies, and care. This ambition is crystallized in our Function Matters™ tagline, which underscores our approach to measuring liver health.
Mission
Our mission is to improve healthcare by providing patients, clinicians, caregivers, researchers and drug developers a tool that accurately measures liver health — across the full spectrum of disease severity — in a cost-effective and minimally invasive way.
Vision
Our vision is to provide the preferred tests for measuring liver health in patients across the globe.
